Boehringer Ingelheim is a research-driven, privately held pharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885, the group develops and markets prescription medicines for human health and a broad range of products for animal health. Its R&D spans therapeutic areas such as cardiovascular-metabolic diseases, respiratory disorders, oncology, immunology, and central nervous system conditions, alongside vaccines and parasiticides in animal health. The company operates a global network of research, development, and manufacturing sites across Europe, the Americas, and Asia.
For the chemical and life-sciences value chain, Boehringer Ingelheim is active in the development and manufacture of small-molecule active pharmaceutical ingredients and finished dosage forms, as well as biopharmaceuticals produced via cell culture and fermentation. Capabilities include chemical process development, scale-up, sterile manufacturing, and quality-controlled vaccine formulation and filling. The company emphasizes high regulatory standards, supply reliability, and ongoing investment in modern production technologies and sustainability across its operations.